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Messenger RNA (mRNA) is a promising platform for both vaccines and therapeutics, and self-
amplifying RNA (saRNA) is particularly advantageous as it enables higher protein expression 
and dose minimization. Here, we present a delivery platform for targeted delivery of saRNA 
using mannosylated poly(ethylene imine) (PEI) enabled by the host-guest interaction between 
cyclodextrin and adamantane. We show that the host-guest complexation does not interfere 
with the electrostatic interaction with saRNA, and observed that increasing the degree of 
mannosylation inhibited transfection efficiency in vitro but enhanced the number of cells 
expressing GFP by 8-fold in human skin explants. Besides, increasing the ratio of 
glycopolymer to saRNA also enhanced the percentage of transfected cells ex vivo. We 
identified that these mannosylated PEIs specifically increased protein expression in the 
epithelial cells resident in human skin in a mannose-dependent manner. This platform is 




Recent advances and investment in RNA technology has enabled messenger RNA 
(mRNA) to become a clinically viable platform for both vaccines and protein replacement 
therapeutics. Self-amplifying mRNA (saRNA) has emerged as a next-generation approach, and 
has several advantages compared to both mRNA and plasmid DNA (pDNA). Because saRNA 
vectors are derived from the alphavirus genome,1 they are able to self-replicate in the 
cytoplasm, resulting in amplification of the delivered dose of RNA and a higher magnitude and 
duration of protein expression than mRNA.2-4 Compared to pDNA, saRNA is a minimal genetic 
vector and does not pose the risk of integration or insertional mutagenesis.5 While a number of 
mRNA vaccines and therapeutics are currently being tested in the clinic,6 there have not yet 
been any non-viral RNA replicons tested in human clinical trials.7   
saRNA has previously been formulated with a variety of delivery platforms, including 
lipid nanoparticles (LNPs),8, 9 a cationic nanoemulsion,3 cationic polymers10, 11 and ionizable 
dendrimers.12 These formulations are not tailored for targeting of certain cell populations, but 
rather increased overall cellular uptake and expression of the saRNA. Liang et al. previously 
observed that while neutrophils, monocytes and dendritic cells infiltrate the injection site and 
take up the RNA, it was mainly monocytes and dendritic cells that translated mRNA formulated 
in LNPs.13 Both siRNA and mRNA has previously been targeted to leukocytes using the 
Anchored Secondary scFv Enabling Targeting (ASSET) platform, in which LNPs are coated 
in monoclonal antibodies to target specific leukocyte subsets.14 Furthermore, siRNA has been 
directly conjugated to a synthetic triantennary N-acetylgalactosamine (GalNAc)-based ligand 
that directly targets hepatocytes in vivo.15 In this study, we sought a delivery platform that 
enabled tailoring of glycosylation without the use of expensive monoclonal antibodies or direct 
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conjugation to saRNA, which is much larger in size than siRNA and unlikely to be taken up 
by cells without complexation. 
Host-guest interactions between cyclodextrin (CD) and adamantane (Ad) have been 
previously used as a gene delivery platform for intravenous delivery of pDNA, wherein 
polyethylene glycol (PEG) was conjugated to adamantane in order to reduce toxicity of a 
poly(ethylene imine) (PEI) formulation.16 CD and Ad are known to form a specific and stable 
complex in aqueous environments through the interaction between adamantane and the 
hydrophobic cavity of CD.17-19 Glycosylation of cyclodextrins has been performed previously, 
and allows for a facile approach for attaching a variety of glycan groups.19, 20 Given the ease of 
chemistry and biocompatibility of CD-Ad complexes, we chose this host-guest pair as a 
platform for glycosylation of PEI as a targeted delivery vehicle for saRNA. 
Herein, we have developed a mannosylated PEI complex enabled by the host-guest 
interaction between CD and Ad. We designed and synthesized a library of PEI polymers with 
varying degrees of mannosylation. We then characterized the polymers and the polyplexes 
formed when complexed with saRNA for size, charge and transfection efficiency in vitro. After 
identifying the optimal ratio of PEI to saRNA, we then tested these formulations ex vivo in a 
clinically relevant human skin explant model to characterize the transfection efficiency. 
Finally, we observed how the degree of mannosylation and ratio of polymer to saRNA affected 
cellular expression and identify of which cellular subsets are targeted. 
2. MATERIALS AND METHODS 
2.1. Materials 
PEI MAX (Transfection grade linear polyethylenimine hydrochloride, MW 40,000) was 
purchased from Polysciences, Inc. Dry triethylamine (TEA) (≥99.5%) equipped with septum, 
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1-adamantane carbonyl chloride and CuBr2 were purchased from Sigma Aldrich and used as 
received. Tris(2-(dimethylamino)ethyl)amine (Me6TREN) was synthesized according to 
literature procedures and stored at 4°C prior to use. Cyclodextrin initiator, mannose 
glycomonomer and heptamannose β-cyclodextrin (CD-Man7) were synthesized as previously 
reported and stored at -20 °C prior to use.21 22 All other reagents and solvents were purchased 
from Sigma Aldrich at the highest purity available and used without further purification unless 
stated otherwise. 
2.2. Instrument and Analysis 
Nuclear Magnetic Resonance (NMR) 
Proton (1H) Nuclear Magnetic Resonance (1H-NMR) spectra were recorded on a 400 
MHz Bruker Avance III spectrometer using DMSO-d6, CDCl3, MeOD-d4 or D2O as the solvent 
at 300K. 2D Nuclear Overhauser Effect SpectroscopY (NOESY) NMR experiments were 
performed on a 600 MHz Bruker Avance NEO spectrometer in D2O at a temperature of 303 K 
using the states-TPPI method with a 5ms Z-gradient spoil pulse in the mixing time and zero-
quantum suppression using the method of M.J. Thrippleton & J.Keeler.23 Mixing time was set 
to 0.3 s, spectra were recorded using 20 scans per t1 increment and the spectral width was set 
to 8 x 8 ppm. 
Dynamic Light Scattering (DLS) 
The hydrodynamic diameters (Dh, the volume weight diameter of the distribution) 
evolution were determined characterized by a Malvern Zetasizer Nano ZS instrument equipped 
with a He−Ne laser at 633 nm. DLS measurements were performed by dissolving polymer 
samples at 1 mg/ml in deionized water and all the samples were passed through a 0.22 µm 
nylon filter before measurement. For complex samples, polymers were dissolved separately in 
deionized water and mixed together at different molar ratios. Then the samples were stirred 
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overnight at room temperature and filtered using a 0.22 nylon filter before analysis. All the 
samples were measured three times at 25 °C. 
In vitro transfection and luciferase assay 
HEK 293T.17 cells (ATCC, USA) were plated at a density of 50,000 cells/well 48 hours 
prior to transfection. The polyplexes were added to each well in a total volume of 100 μL with 
a total dose of 100 ng of RNA in 20 mM HEPES with 5% glucose with n=3. The cells were 
then incubated with the polyplexes for 4 hours, and then the media was replaced with 100 μL 
of complete Dulbecco’s Modified Eagle’s Medium (cDMEM) (with 10% fetal bovine serum 
(FBS), 5 mg/mL L-glutamine, 5 mg/mL penicillin streptomycin (ThermoFisher, UK)). After 
24 hours, 50 uL of media was removed and 50 uL of ONE-Glo™ luciferase substrace 
(Promega, UK) was added, and the total 100 μL was transferred to a white 96-well plate and 
analyzed on a FLUOstar Omega plate reader (BMG LABTECH, UK) with a gain of 4000. The 
average of the media only wells were subtracted from each sample measurement. 
Human skin explant culture and digestion 
Surgically resected specimens of human skin tissue were collected at Charing Cross 
Hospital, Imperial College London, UK. All tissues were collected after receiving signed, 
informed consent from all patients under protocols approved by the Local Research Ethics 
Committee. The tissue was obtained from patients undergoing elective abdominoplasty, breast 
reduction or mastectomy surgeries. Tissue was refrigerated until arrival in the laboratory. The 
subcutaneous layer of fat was completely removed, and the remaining skin layers were trimmed 
into ~1 cm2 sections. Explants were cultured in 10 mL of cDMEM in a petri dish at 37 °C and 
5% CO2, and the media was refreshed daily.  
Explants were injected with 2 μg of saRNA in a volume of 50 μL intradermally (ID) 
using a Micro-Fine Demi 0.3 mL syringe (Becton Dickinson, UK). After 3 days, skin was 
 7 
digested as previously described.9 Briefly, explants were minced well with scissors and 
incubated in 2 mL DMEM supplemented with 1 mg/mL collagenase P (Sigma, UK) and 5 
mg/mL dispase II (Sigma, UK) for 4 hours at 37°C on a rotational shaker. Digests were then 
filtered through a 70 μm cell strainer and centrifuged for 5 min at 1750 RPM. Cells were 
resuspended in 100 μL of FACS buffer (PBS + 2.5% FBS) and stained with 100 μL of Aqua 
Live/Dead Stain (ThermoFisher, UK) diluted 1:400 in FACS buffer for 20 min on ice. Cells 
were then washed with 1 mL of FACS buffer, centrifuged at 1750 RPM for 5 min and stained 
with a panel of antibodies (Supplementary Table 1) to identify cellular phenotypes for 30 
minutes. Cells were then washed with 1 mL of FACS buffer, centrifuged at 1750 RPM for 5 
minutes and resuspended in 250 μL of PBS. Cells were fixed with 250 μL of 3% 
paraformaldehyde for a total concentration of 1.5% and refrigerated until flow cytometry 
analysis.   
Flow cytometry analysis 
Single cell suspensions were analyzed on a LSRFortessa™ (BD Biosciences, UK) 
using FACSDiva software (BD Biosciences, UK) with 100,000 acquired events. Gating was 
performed as previously described.9 GFP+ cells and phenotypes were quantified using FlowJo 
Version 10 (FlowJo LLC, Oregon, USA).  
Statistical analysis 
Graphs and statistical analysis of in vitro and ex vivo data were prepared in GraphPad 
Prism, version 8.0. Statistical analysis was performed using a two-tailed t test or a one way 
ANOVA adjusted for multiple comparisons with α=0.05 used to indicate significance.  
2.3. Methods 
General procedure for adaPEI synthesis 
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Linear polyethylene imine hydrochloride 40 kDa (PEI, 100 mg, 2.5 x 10-6 mol) was 
suspended in 40 mL dry CHCl3 in a 100 mL RBF under Ar, equipped with stirring bar and 
sonicated for 30 min. Subsequently the suspension was stirred and 1 mL of dry TEA was added. 
Afterwards, the suspension was sonicated for 30 min until a fine suspension was achieved. A 
solution of adamantane carbonyl chloride (50 mg, 2.515 x 10-4 mol, 0.2 eq. per repeating unit) 
in 10 mL dry CHCl3 was prepared and subsequently added to the suspension. The mixture was 
allowed to stir overnight at ambient temperature. After the reaction the suspension was filtered 
over the MilliPore and an NMR sample was taken in D2O. Subsequently the filtered residue 
was dissolved in 10 mL H2O to which 1 mL of a 32% HCl solution in water was added. The 
solution was subsequently precipitated in acetone and dried under vacuum. An NMR sample 
was taken in D2O and average amount of adamantanes per chain were calculated by comparing 
the CH2- peak to the amount of adamantane protons.  Quantities for synthesis of other adaPEIs 
can be found in Table S1 and S2. 
SET-LRP polymerization of CD-p(Man8)7  
A Schlenk tube was charged with CD7-initiator (10 mg, 2696.88 g/mol, 3.71 µmol), 
mannose glycomonomer (291 mg, 373.36 g/mol, 779 µmol, 30 eq. per initiating site), 
Me6TREN (1.32 µL, 4.93 µmol, 0.19 eq. per initiating site), CuBr2 (232 µg, 1.04 µmol, 1.04 
eq. per initiating site) in DMSO (2 mL), sealed with a rubber septum and subsequently degassed 
by gentle bubbling of Ar gas for 15 min. The polymerization was then started by addition of 
pre-activated Cu(0) wire (5 cm) wrapped around a stirring bar under a positive Ar pressure and 
quickly sealed again and the reaction mixture was allowed to polymerize for 1 h at 25˚C. 
Sampling was carried out using a degassed syringe to check the conversion of mannose 
glycomonomer. NMR samples was dissolved in DMSO-d6 and conversion was determined as 
27.5% (8.3 monomers per arm) by comparing the triazole peak to the vinyl protons. After 
polymerization the glycopolymer CD-p(Man8)7 was dialysed against water to remove excess 
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glycomonomer and further impurities. Molecular weight of the polymer was then determined 
via 1H NMR and was revealed to be 24.5 kDa on average. 
Synthesis of glycoPEI: Complexation of adaPEI with CD-Man7  
A solution of adaPEI2 (30.2 mg, 41088 g/mol, 0.734 µmol) and CD-Man7 (17.9 mg, 
2836.53 g/mol, 6.26 µmol, 8.58 eq. per polymer chain) was prepared in 10 mL H2O amounting 
to a 1 / 1 ratio of cyclodextrin derivative per adamantane and sonicated until the solution 
became clear. Subsequently the solution was transferred to a 20 mL glass vial and freeze-dried. 
An NMR sample was made by dissolving 10 mg in D2O for Nuclear Overhauser Effect 
Spectroscopy (NOESY). Quantities for synthesis of other adaPEIs can be found in Table S1. 
Synthesis of glycoPEI: Complexation of adaPEI with CD-(pMan8)7  
A solution of adaPEI1 (30.7 mg, 41390 g/mol, 0.741 µmol) and CD-(pMan8)7 (86 mg, 
24499 g/mol, 3.51 µmol, 4.75 eq. per polymer chain) was prepared in 10 mL H2O amounting 
to a 1 / 1 ratio of gycopolymer CD-(pMan8)7 per adamantane and sonicated until the solution 
became clear. Subsequently the solution was transferred to a 20 mL glass vial and freeze-dried.  
saRNA synthesis and purification 
Self-amplifying RNA encoding the non-structural proteins (NSPs) from the 
Venezuelan Equine Encephalitis Virus (VEEV) and either firefly luciferase (fLuc) or enhanced 
green fluorescent protein (eGFP) was prepared using in vitro transcription. pDNA was 
transformed into Eschericia coli and cultured in 50 mL of LB broth with 1 mg/mL carbenicillin 
(Sigma Aldrich, UK) and isolated using a Plasmid Plus Maxiprep kit (QIAGEN, UK). pDNA 
concentration and purifity were quantified on a NanoDrop One (ThermoFisher, UK) and then 
linearized using MluI for 3 h at 37 °C. Co-transcriptionally capped saRNA, used for in vitro 
experiments, was synthesized using 1 μg of linearized DNA template in a mMessage 
mMachine reaction (Ambion, UK) according to the manufacturer’s protocol, and purified using 
 10 
a MEGAclear column (Ambion, UK) according to the manufacturer’s protocol. For ex vivo 
experiments, uncapped in vitro RNA transcripts were synthesized using 1 μg of linearized DNA 
template in a MEGAScript reaction (Ambion, UK) according to the manufacturer’s protocol. 
Transcripts were then purified by overnight LiCl precipitation at -20 °C, pelleted by 
centrifugation at 14,000 RPM for 20 min at 4°C, washed with 70% EtOH, centrifuged at 14,000 
RPM for 5 min at 4°C, and then resuspended in UltraPure H2O. Purified transcripts were then 
capped using the ScriptCap™ and m7G Capping System (CellScript, Madison, WI, USA) and 
ScriptCap™ 2’-O-Methyltransferase Kit (CellScript, Madison, WI, USA) simultaneously 
according to the manufacturer’s protocol. Capped transcripts were then purified again by LiCl 
precipitation and stored at -80 °C in a buffer of 10 mM HEPES with 100 mg/mL trehalose until 
use. 
Particle complexation and characterization 
Stock solutions of glycopolymers were prepared at a concentration of 5 mg/mL in 
ultrapure H2O and purified using a 0.22 μm syringe filter (Millipore, Sigma, UK). saRNA 
complexes were prepared by mixing the RNA and polymer in 20 mM HEPES buffer (pH 7.4) 
with 5% glucose, with a ratio of polymer to RNA of 5:1 (w/w) unless otherwise specified. The 
solution was immediately vortexed for 30 seconds and then allowed to rest for 10 minutes prior 
to use. 
Polyplexes were prepared in a volume of 800 μL of 20 mM HEPES with 5% glucose 
for particle size and charge analysis, and characterized on a Zetasizer NanoZS (Malvern 
Instruments, UK) with Zetasizer 7.1 software (Malvern Instruments, UK) in a clear disposable 
1 mL cuvette. The polyplexes were analyzed using the following settings: a material refractive 
index of 1.529, absorbance of 0.010, dispersant viscosity of 0.8820 cP, refractive index of 1.330 
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and dielectric constant of 79. Each sample was analyzed three times for up to 100 runs or until 
the measurement stabilized. 
Synthesis of per-(6-deoxy-6-bromine)-β-cyclodextrin  (β-CD-(Br)7) 
Triphenylphosphine (Ph3P, 36.72 g, 140 mmol) was dissolved in anhydrous DMF (150 
mL) under stirring and cooled down to 0 °C (Scheme S1). N-bromosuccinimide (NBS, 24.92 
g, 140 mmol) was dissolved in anhydrous DMF (40 mL) and the solution was added dropwise 
to the Ph3P solution under Ar atmosphere and then stirred at ambient temperature for 30 min. 
β-Cyclodextrin (β-CD, 11,35 g, 10 mmol) (previously recrystalized three times from water and 
dried in vacuum oven at 50 °C for two days) was dissolved in anhydrous DMF (150 mL). The 
obtained Ph3P/NBS solution was then added dropwise to the β-cyclodextrin solution at ambient 
temperature after which the solution temperature was increased to 80 °C. The mixed brown 
solution was stirred under Ar atmosphere overnight at 80 °C. Afterwards MeOH (40 mL) was 
added at ambient temperature and stirring was continued for 30 min. The reaction mixture was 
then cooled to 0 °C and the pH was adjusted to 9 by adding sodium methoxide, while further 
stirring for 1 h. The reaction mixture was then poured into stirred ice-water (4 L) resulting in a 
fine precipitate which was filtered and washed with MeOH. Heptakis (6-deoxy-6-bromo)-β-
cyclodextrin was obtained as beige solids and dried under vacuum for 1 day. Yield: 11.32 g, 
70%). 
1H NMR (400 MHz, DMSO-d6, 298 K, ppm): δ =6.02 (d, 7 H, 6.7 Hz), 5.89 (d, 7 H, 1.9 Hz), 
4.98 (d, 7 H, 3.4 Hz), 4.00 (d, 7 H, 9.8 Hz), 3.82 (t, 7 H, 9.3 Hz), 3.65 (m, 14 H), 3.38 (m, 14 
H, overlap with H2O). 
MALDI-TOF MS m/z: calculated for C42H63Br7O28K




Synthesis of per-(6-deoxy-6-azido)-β-cyclodextrin  (β-CD-(N3)7) 
Heptakis (6-deoxy-6-bromo)-β-cyclodextrin (10 g, 6.3 mmol) was dissolved in 
anhydrous DMF (80 mL) and NaN3 (5.78 g, 88.8 mmol) (Scheme S2). The resulting 
suspension was stirred at 70 °C under Ar for 36 h. The suspension was then allowed to cool 
down and precipitated in 2 L of stirred ice-water. The precipitate was filtered, washed with 
water and redissolved in DMF (20 mL) and precipitated in 1L of stirred ice-water. The 
precipitate was filtered and washed with water and with little acetone. The resulting product 
was a white solid (yield: 7.2 g, 86.5 %) and was dried under vacuum overnight.   
1H NMR (400 MHz, DMSO-d6, 298 K, ppm): δ =5.90 (d, 7 H, 6.8 Hz), 5.75 (d, 7 H, 2 Hz), 
4.91(d, 7 H, 3,4 Hz), 3.74 (m, 14 H), 3.59 (m, 14 H), 3.36 (m, 14 H, overlap with H2O).  
MALDI-TOF MS m/z: calculated for C42H63N21O28K
+: 1348.37; found, 1348.27. 
Synthesis of per-6-thio-β-cyclodextrin (β-CD-(SH)7) 
β-CD-(Br)7 (5 g, 3.17 mmol) and thiourea (2.5 g, 33.3 mmol) were dissolved in DMF 
(50 mL) and the mixture was heated to 70 °C under argon atmosphere (Scheme S3). After 24 
h, DMF was removed under reduced pressure and the obtained brown oil was dissolved in 
water (200 mL). Sodium hydroxide (2.22 g, 55.5 mmol) was then added and the reaction 
mixture was heated to a gentle reflux under nitrogen atmosphere. After 1 h, the resulting 
suspension was acidified with aqueous KHSO4 forming a white precipitate which was then 
filtered and washed thoroughly with water and dried under vacuum. Compound β-CD-SH was 
recovered as white powder (yield: 3.2 g, 81%).  
1H NMR (400 MHz, DMSO-d6, 298 K, ppm): δ =5.91 (d, 7 H, 6.8 Hz), 5.81 (d, 7 H, 2 Hz), 
4.93(d, 7 H, 3.3 Hz), 3.68 (t, 7 H, 8.5 Hz), 3.61 (t, 7 H, 9.2 Hz), 3.29-3.40 (m, 14 H, overlap 
with H2O), 3.19 (m, 7H), 2.75 (m, 7 H), 2.13 (t, 7 H, 8.3 Hz). 
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Synthesis of allyl 2-bromoisobutyrate 
Allyl alcohol (16.2 mL, 16.42 g, 282 mmol) and triethylamine (47.3 mL, 34.33 g, 339 
mmol) were dissolved in diethyl ether (150 mL) and cooled down to 0 °C in an ice-water bath 
(Scheme S4). A solution of α-bromoisobutyryl bromide (BIBB) (27 mL, 50 g, 217 mmol) in 
20 mL diethyl ether was added dropwise over a period of 20 min. The mixture was allowed to 
stir for 1 h at 0 °C after which it was allowed to reach room temperature and stirring was 
continued overnight. The solution was washed 3 x 50 mL 10% HCl solution, 3 x 50 mL 5% 
NaOH solution, 3 x 50 mL water and subsequently dried over MgSO4. After evaporating the 
solvent via rotary evaporation, the product was purified by flash chromatography on silica gel 
using chloroform as an eluent affording a colourless oil. (yield: 76%, 23 g). 
1H NMR (400 MHz, CDCl3, 298 K, ppm): δ = 5.9 (ddt, 1 H, 5.5 Hz, 10.6 Hz, 17.2 Hz), 5.35 
(dq, 1 H, 1.5 Hz, 17.2 Hz), 5.24 (dq, 1 H, 1.3 Hz, 10.6 Hz), 4.63 (dt, 2 H, 1.4 Hz, 5.6 Hz), 1.91 
(s, 6 H). 
Synthesis of per-6-deoxy-6-(thiopropyl-2-bromo-2-methylpropanoate)-β-cyclodextrin 
Per-6-thio-β-cyclodextrin (2.5 g, 2 mmol), and dithiothreitol (DTT, 618 mg, 4 mmol) 
were dissolved in 40 mL anhydrous DMF under Ar and heated to 60 °C (Scheme S5). After 
60 h de reaction mixture was allowed to cool down to room temperature and allyl 2-
bromoisobutyrate (14.53 g, 70 mmol), 2,2-dimethoxy-2-phenylacetophenone (DMPA, 179 mg, 
7 mmol) were added to the reaction mixture and stirring was continued for 5 h under UV 
irradiation (365 nm). 
The solution was precipitated in 500 mL of methyl tert-butyl ether (MTBE) in ten 50 
mL centrifuge tubes and centrifuged at 8000 rpm for 5 min. The solvent was decanted and all 
precipitated fractions collected in two 50 mL centrifuge tubes and fresh MTBE was added, 
mixed and centrifuged again. This procedure was repeated 4 times in order to remove DMF 
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and allyl 2-bromoisobutyrate. Subsequently the product was dried under vacuum, yielding a 
fine beige solid. (3.7 g, yield: 68%).  
1H NMR (400 MHz, DMSO-d6, 298 K, ppm): δ = 5.90 (d, 7 H, 5.6 Hz), 5.8 (m, 7 H), 4.85 (m, 
7 H), 4.22 (t, 14 H, 5.2 Hz), 3.85 (m, 7 H), 3.57 (m, 7 H), 3.33 (m, 14 H), 3.09 (d, 7 H, 10.6 
Hz), 2.82 (m, 7 H), 2.69 (m, 14 H), 1.90 (s, 56 H). 
MALDI-TOF MS m/z: calculated for C91H147Br7O42S7K
+:2733.12; found: 2733.36. 
Synthesis of 3-azido-propan-1-ol 
3-bromopropan-1-ol (7 g, 50.35 mmol) was dissolved in a solution of acetone (250 mL) 
and water (50 mL) along with sodium azide (1.6 eq., 5.56 g, 86.61 mmol) and refluxed 
overnight at temperature of 70 °C (Scheme S6). The organic solvent was removed by rotary 
evaporation. 50 mL water was added to the remaining water phase and was then extracted with 
diethyl ether (3X50 mL). The resulting ether phase was then back extracted with water (50 mL) 
and dried over magnesium sulphate. The organic solvent was removed by rotary evaporation. 
The product was recovered as a colourless liquid and used directly (yield: 64%). 
1H NMR (400 MHz, D2O, 298 K, ppm): δ =3.66 (t, 2 H, 6.3 Hz), 4.41 (t, 2 H, 6.8 Hz), 1.81 
(quin, 2 H, 6.5 Hz). 
13C NMR (100 MHz, D2O, 298 K, ppm): δ = 58.78 (O-CH2), 47.93 (CH2-N3), 30.49 (C-CH2-
C). 
ESI-MS m/z: calcd for C6H9N3O2 (2M+H
+), 311.1; found, 311.1. 
Notice: Organic azide is very sensitive compound and it should be handled with great care. 
After synthesis this intermediate was directly used for the next step reaction without further 
purification. Long period storage even in the fridge is not recommended.  
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Synthesis of 3-azidopropyl acrylate 
A solution of 3-azido-propan-1-ol (6.10 g, 60.3 mmol), TEA (8.5 mL, 84.5 mmol), 
hydroquinone (30 mg) and anhydrous diethyl ether (200 mL) was cooled in an ice water bath 
(Scheme S7). Acryloyl chloride (5.88 mL, 72.4 mmol) in 20 mL diethyl ether was added 
dropwise into the solution. The mixture was stirred in the ice bath for 1 h and then at ambient 
temperature overnight. The ammonium salts were removed by filtration and the residue was 
extracted sequentially with aqueous solution of hydrochloric acid (10 v%, 3X50 mL), water 
(2Х50 mL), 5 wt% aqueous NaOH (3Х50 mL) and water (2Х50 mL) and dried over 
magnesium sulphate. The organic solvent was removed by rotary evaporation.  The product 
was recovered as a yellow liquid and used directly (yield: 45%). 
1H NMR (400 MHz, CDCl3, 298 K, ppm): δ =6.42 (dd, 1 H, 1.4, 17.3 Hz), 6.12 (dd, 1 H,10.4, 
17.3 Hz), 5.85 (dd, 1 H, 1.4, 10.4 Hz), 4.25 (t, 2 H, 6.2 Hz), 3.41 (t, 2 H, 6.7 Hz), 1.96 (quin, 2 
H, 6.4 Hz). 
Synthesis of 1-(2′-Propargyl) D-Mannose 
1-(2′-Propargyl) D-Mannose was prepared according to the procedure reported by 
Mukhopadhyay et al.54 A suspension solution of D-Mannose (12 g, 66.6 mmol), propargyl 
alcohol (19.4 mL, 333 mmol) and H2SO4-silica (333 mg) was stirred at 65 °C overnight 
(Scheme S8). After cooling to ambient temperature, the reaction mixture was transferred to a 
silica gel column and eluted with CHCl3-MeOH (8:1) to remove the excess propargyl alcohol. 
1-(2′-Propargyl) D-Mannose was obtained as a white solid after drying under vacuum (8 g, 
yield: 55 %). 1-(2′-propargyl) D-Mannose was found as an anomeric mixture in a ratio of 10:1 
(α/β).  
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1H NMR (400 MHz, CD3OD, 298 K, ppm): δ: 4.96 (d, 1H, 1.6 Hz), 4.27 (d, 2H, 2.5 
Hz), 3.84 (dd, 1H, 2.3, 11.8 Hz), 3.79 (dd, 1H, 1.8, 3.1 Hz), 3.66 (m, 3H), 3.51 (m, 1H), 2.85 
(t, 1 H, 2.4 Hz)  
Synthesis of D-Mannose glycomonomer 
1-(2′-propargyl) D-mannose (2.46 g, 12.6 mmol) and 3-azidopropyl acrylate (2.85 g, 
11.8 mmol) were dissolved in MeOH/H2O (2:1 vol/vol, 60 mL), aqueous solution of 
CuSO4·5H2O (246 mg, 0.9 mmol) and (+)-sodium L-ascorbate (284 mg, 1.2 mmol) were added 
into the reaction solution (). The reaction mixture was stirred at ambient temperature for 24 h 
and then the methanol was removed under vacuum and residue mixture was freeze dried to 
remove water. The purification of the obtained product was done by silica gel column 
chromatography using dichloromethane-MeOH (8:1) as eluent. After the removing of solvent, 
the product was obtained as white (1.62 g, yield: 58.2%).  
1H NMR (D2O, 298 K, 400 MHz): δ =8.07, 8.06 (s, overlaped, 1 H, NCH=C), 6.37 (dd, J=1.8, 
15.5 Hz), 6.36 (dd, J=1.6, 15.7 Hz) (anomeric 1 H, CH2=C), 6.14 (dd, J=10.4, 6.9 Hz), 6.13(dd, 
J=10.4, 7.0 Hz) (anomeric, 1 H, CH2=CHC=O), 5.89 (dd, 1 H, J=1.5, 8.9 Hz, CH2=C), 4.70-
5.05 (m, CH2-OH, H-1 of mannose , overlap with H2O), 4.64 (d, 1 H, J=12.3 Hz, CH2-OH), 
4.55 (t, 2 H, J=6.9 Hz, CH2-N), 4.19 (t, 2 H, J=6.0 Hz, C=O-O-CH2), 3.40-3.92 (m, H residues 
of mannose), 2.30 (m, 2H, CH2-CH2-CH2) ppm.  
13C NMR (D2O, 298 K, 400 MHz): δ =146.4 (C=O), 145.4 (N-CH=C), 131.9 (CH2=C), 129.2 
(CH2=C), 125.6 (N-CH=C), 100.8 (β anomeric, C1 of mannose), 100.7 (α anomeric, C 1 of 
mannose), 78.4,75.2, 75.0, 72.5, 72.3, 72.0, 68.6, 68.4 (carbons of anomeric mannose), 
63.0(CH2-OH), 62.6 (C=O-O-CH2), 60.7 (C-CH2-O), 48.5 (CH2-CH2-N), 28.5(CH2-CH2-CH2) 
ppm. 
ESI-MS m/z: calcd for C15H23N3O8 (M+Na
+), 396.1; found, 396.1. 
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Synthesis of heptamannose β-cyclodextrin (CD-(Man)7).  
β-CD-(N3)7 (1.96 g, 1.5 mmol), 1-(2‘-propargyl)-D-Mannose (2.61 g, 12 mmol) were 
dissolved in DMSO (20 mL) in a Schlenk tube (Scheme S10). Bipyridine (0.37 g, 0.0024 
mmol) and CuBr (0.17 g, 0.0012 mmol) were added. The resulting mixture was evacuated and 
filled with argon and 3 freeze-pump-thaw cycles were performed to eliminate oxygen from the 
reaction mixture. The mixture was then allowed to stir at 50 °C for 24 h. After the reaction, 
water was added to the reaction medium and the resulting mixture was dialysed against water. 
After dialysis, the resulting clear solution was freeze dried. 
1H NMR (DMSO-d6, 298 K, 400 MHz): δ = 7.95, 7.92 (s, overlapped, 7 H, NCH=C), 5.80-
6.10 (m, 14 H, OH-2, OH-3 of CD), 5.10 (s, 7 H, H-1), 3.00-5.00 (m, CD & mannose residues, 
overlap with H2O) ppm. 
3. RESULTS AND DISCUSSION 
3.1 Preparation and Characterization of Mannosylated PEI Polymers 
A library of different PEI based polymers were successfully modified to contain 
appending adamantane units along the backbone. For this, commercially available PEI was 
first deprotonated using triethylamine and subsequently reacted with 1-adamantane carbonyl 
chloride via a simple substitution reaction (Figure 1A). The resulting adaPEI polymers were 
protonated and furthermore characterized using 1H-NMR (Figure 1B) in order to determine 
the average adamantane content per polymer chain together with the change in molecular 
weight (Table 1). Protonation shifts PEI peak (-CH2-CH2-) from around 3.0 ppm to around 3.5 
ppm. Percentages are defined as the percentage of monomer units along the polymer backbone. 
1H- NMR analysis revealed that there is a huge discrepancy between the amount of adamantyl 
groups added to the reaction and adamantyl actually found along the polymer chain.  
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Figure 1. Chemical reaction scheme for the synthesis of adaPEI (4) and glycoPEI (6) (A); 1H 
NMR characterization of the synthesized adaPEI1 (B). 
Apart from a monodisperse heptamannose β-cyclodextrin (CD-Man7) previously 
synthesized within the group, a cyclodextrin based star-shaped mannose polymer was also 
prepared. Mannose monomer was synthesised as previously reported (analysis provided in ESI) 
and subsequently used for polymerisation starting from a heptavalent β-cyclodextrin based 
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initiator.21, 22 The polymerisation proceeded via Single Electron Transfer-Living Radical 
Polymerisation (SET-LRP) in DMSO for 1h and was followed via 1H-NMR. 
 
Table 1. Characteristics of the synthesized glycoPEI polymers before supramolecular 
interaction and after the supramolecular interaction.   
aTheoretical amount of adamantane before the reaction; bThe amount of  adamantane according to 1H NMR after the reaction; 
cThe number of adamantane per chain according to 1H NMR; dThe molecular weight of the polymers according to 1H NMR 
after the reaction; eThe molecular weight of the polymers according to 1H NMR after the complexation with CD.     
 
The resulting adaPEIs were subsequently mannosylated in a supramolecular manner by 
combining the adaPEIs with CD-Man7 or CD-(pMan8)7 in water. The resulting glycoPEIs were 
then characterized via 1H-NMR, 2D NOESY NMR and DLS which confirmed the anticipated 
host-guest complexation between the adamantyl groups and CD-Man7 as NOESY experiments 
revealed cross-peaks between the signals at 4 – 4.3 ppm assigned to the inner protons of the 
CD-Man7 cavity and the signals at 1.9 – 2.4 ppm assigned to the adamantane not present when 
taken 2D NOESY from the respective pure products (Figure 2A). Additionally, as seen in 
Figure 2B, the host-guest interaction between PEI1 and CD-Man7 was further confirmed by 
DLS,  which  revealed  that  size  and  size  distribution  increased  due  to  the  attachment  of  






PEI1 40 2.18 10.96 41390 72560 
PEI2 20 1.71 8.58 41080 65480 
PEI3 10 0.94 4.76 40600 54090 
PEI4 5 0.54 2.72 40340 48060 
PEI5 2.5 0.37 1.83 40230 45440 
PEI6 1.25 0.14 0.71 40090 42110 
PEI7 10 0.94 4.76 40600 157110 
PEI 0 0 0 40000 - 
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Figure 2. 2D NOESY-NMR spectrum of the adaPEI1 and CD-Man7, clearly showing cross 
peaks between the signals at 4.0 – 4.3 ppm assigned to the inner protons of the CD-Man7 cavity 
and the signals at 1.9 – 2.4 ppm assigned to the adamantane (A); DLS measurements of the 
adaPEI1 and CD-Man7 before and after supramolecular interaction (B). 
CD-Man7 on the backbone of PEI1. The mean hydrodynamic size of PEI1 increased 
dramatically from 125 nm to 218 nm while distribution index increased from 0.34 to 0.58 after 
the host-guest complexation. Besides, large aggregates of CD-Man7 disappeared after the 
complexation, which also proved that the interaction of CD-Man7 with adamantane units on 
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the polymer backbone could eliminate the formation of interchain assemblies of aggregations. 
The resulting solutions were furthermore freeze-dried, resulting in a fine powder which is 
easily dissolvable for use in RNA transfection. 
3.2 Preparation and Characterization of saRNA/ManPEI Polyplexes In Vitro 
Particle size and charge was characterized after complexation with saRNA (Figure 3). 
All particles were found to be between 50-200 nm in size, with a slight trend of increasing size 
with increasing degree of mannosylation. All particles were positively charged after saRNA 
complexation, indicating that the host-guest interaction does not interfere with the cationic 
charges or further condensation of saRNA molecules.  
 
Figure 3. Particle size and zeta potential of PEI-Ad-CD-Man7/saRNA polyplexes as 
determined by DLS. Z-average particle diameter (the volume weight diameter of the 
distribution) (A) and zeta potential (B) of complexes prepared at a ratio of 5:1 polymer to RNA 
(w/w). Bars represent mean ± standard deviation for n=3. 
In order to investigate the effects of the ratio of PEI to saRNA and degree of 
mannosylation on transfection efficiency in vitro, we prepared polyplexes with saRNA and PEI 
polymers with and without mannosylation. We observed how the degree of mannosylation 
affected transfection efficiency, using either unmodified PEI, PEI with varying amounts of 
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Man7 (PEI1-6) or PEI with polyMan7 (PEI7) (Figure 4A). Because changing the mass ratio of 
polymer to saRNA changes the amount of available positively charges amines, we used a fixed 
ratio of PEI to saRNA of 5:1 (w/w) and then normalized the molar amount of PEI in each 
formulation for PEI1-7. We observed that PEI had the highest transfection efficiency, ~10
6 RLU, 
whereas all of the mannosylated PEIs were lower, between 1-5x105 RLU. In addition, 
increasing the degree of mannosylation decreased the transfection efficiency in vitro, as PEI4-
6 had the highest transfection efficiency of the mannosylated PEIs, and PEI1-3 had the lowest. 
We hypothesize that this is due to steric hinderance cause by increasing degree of 
mannosylation which may limit the access that saRNA has to the amine groups on PEI. 
 
Figure 4. In vitro transfection efficiency of PEI-Ad-CD-Man7 complexes with fLuc saRNA in 
HEK293T.17 cells after 24 hours. Transfection efficiency with formulations normalized to the 
molar amount of PEI in the complex (A); Transfection efficiency with formulations prepare by 
varying ratio of polymer to RNA. Bars represent mean ± standard deviation for n=3 (B). 
Furthermore, while HEK cells can be induced to express the mannose receptor,24 they 
do not naturally express it, thus these experiments exhibit how the structure of the polyplexes 
affects non-mannose mediated uptake. Furthermore, we observed similar transfection 
efficiency between the 5:1 and 20:1 ratios of polymer to saRNA (w/w) in vitro (Figure 4B). 
This is most likely due to glycopolymers being saturated with saRNA even at lower ratios of 
polymer to RNA, which is supported by the Zetasizer data (Figure 3) wherein even at a ratio 
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of 5:1, the particles exhibit a positive charge. Thus, adding more polymer does not increase the 
transfection efficiency. Overall, we observed that increasing the degree of mannosylation, but 
not the ratio of mannosylated PEI to saRNA, decreased the transfection efficiency in vitro. 
3.3 Transfection Efficiency of saRNA/ManPEI Polyplexes in Human Skin Explants. 
Because in vitro transfection efficiency does not generally correlate well with in vivo 
efficacy,25 we sought to test these glycopolymers in a clinically translational human skin 
explant model. Human skin explants have previously been shown to be a viable model for 
optimization of nucleic acid formulations,9 and contain many cell types with the mannose 
receptor including dendritic cells, fibroblasts, and macrophages.26-30 We first prepared 
formulations with either RNA alone, PEI or mannosylated PEI (PEI1-6) (Figure 5A) at a ratio 
of 5:1 polymer to saRNA (w/w). We were surprised to observe that the polyplexes did not 
enhance the percentage of eGFP+ in skin explants, even with unmodified PEI (Figure S6A). 
We observed a similar effect for PEI with polyMan7- only ~1% of cells expressed GFP and 
there was no observed benefit to naked RNA alone (Figure S6B). We then tested whether 
increasing the ratio of PEI1 to saRNA had any effect on the percentage of cells expressing GFP 
(Figure 5B). We observed that increasing the ratio of PEI1 to saRNA to 10:1 and 20:1 (w/w) 
did indeed increased the number of GFP+ cells to 5% and 8%, with p=0.018 and 0.00038, 





Figure 5.  Ex vivo transfection efficiency in human skin explants. Percentage of eGFP+ 
epithelial cells in human skin explants after ID injection of saRNA/ PEI-Ad-CD-Man7 
complexes prepared at a ratio of 20:1 (w/w) after 72 hours in culture. Bars represent mean ± 
standard deviation for n=3. * indicates significance of p<0.05 (A); Percentage of eGFP+ cells 
in human skin explants after treatment with saRNA/PEI-Ad-CD-Man7 complexes after 72 
hours in culture. The ratio of complexes to RNA was varied from 1:1 to 20:1 (w/w) of PEI1. 
Bars represent the mean ± standard deviation for n=3. * indicates significance of p<0.05 
compared to RNA only(B).  
3.4 Impact of Ratio of ManPEI to saRNA on Ex Vivo Phenotypic Protein Expression 
We then characterized which cells were expressing the saRNA using a flow cytometry 
panel capable of identifying epithelial cells (CD45-), fibroblasts (CD90+), NK cells (CD56+), 
leukocytes (CD45+), Langerhans cells (CD1a+), monocytes (CD14+) dendritic cells 
(CD11c+), T cells (CD3+) and B cells (CD19+). As previously observed, the majority of cells 
that make up the skin are epithelial cells, fibroblasts and dendritic cells, and leukocytes, 
Langerhans cells, B cells, monocytes and T cells to a lesser extent (Figure 6A). While epithelial 
cells make up ~64% of the total cells, they make up only 16% of the cells expressing the saRNA 
alone. However, when the saRNA was complexed with mannosylated PEI1 at a ratio of 20:1 
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(w/w), it was expressed in ~33% of epithelial cells (Figure 6B). GFP was expressed in either 
a similar or lesser percentage of the other cell types. Overall, we observed that increasing the 
ratio of mannosylated PEI to saRNA increased the number of cells expressing saRNA in human 
skin explants, and we identified that epithelial cells were specifically targeted by these 
polyplexes. 
 
Figure 6. Phenotypic identity of eGFP+ cells in human skin explants alone (A) and after ID 
injection of GFP saRNA/PEI-Ad-CD-Man7 complexes at varying ratios of PEI1 to saRNA (B). 
Cells were identified using the following antibodies: epithelial cells (CD45-), fibroblasts 
(CD90+), NK cells (CD56+), leukocytes (CD45+), Langerhans cells (CD1a+), monocytes 





3.5 Impact of Degree of Mannosylation on Phenotypic Expression of saRNA Ex Vivo 
Given our observation that increasing the ratio of mannosylated PEI to saRNA enhanced the 
number of cells expressing saRNA, we then studied whether the degree of mannosylation 
affected cellular uptake and expression ex vivo (Figure 7). We prepared polyplexes at a fixed 
ratio of 20:1 (w/w) of PEI to saRNA and again evaluated which cells were expressing GFP. 
We observed that at a ratio of 20:1, the PEI formulations (both unmodified and mannosylated) 
increased the percentage of GFP+ cells to ~8%. Increasing the degree of mannosylation had a 
trend of increasing the percentage of epithelial cells expressing GFP (Figure 7), although only 
the PEI1,2,4,6 groups were found to be statistically significantly higher.  While the mannose 
receptor is primarily known to be expressed by macrophages, dendritic cells, fibroblasts and 
keratinocytes, it has previously been shown to be expressed by vaginal epithelial cells.31 It is 
possible that human skin epithelial cells also express the mannose receptor, leading to increased 
polyplex uptake and saRNA expression in these cells. However, in these studies we quantified 
the percentage of cells expressing the saRNA, not the percentage of cellular uptake, so it is 
possible that there is increased uptake into cells that are known to express the mannose receptor. 
In the context of RNA vaccines, it has yet to be defined as to which cells are desired to express 
the protein; we hypothesize that an increased protein expression will result in increased 
immunogenicity. Overall, we show that increasing the degree of mannosylation increases 
protein expression, specifically in epithelial cells of human skin explants.  
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Figure 7. Phenotypic identity of eGFP+ cells in human skin explants after ID injection of 
saRNA/PEI-Ad-CD-Man7 complexes prepared at a ratio of 20:1 (w/w) with PEI1-7 after 72 
hours in culture. Cells were identified using the following antibodies: epithelial cells (CD45-), 
fibroblasts (CD90+), NK cells (CD56+), leukocytes (CD45+), Langerhans cells (CD1a+), 





A library of mannosylated PEI polymers enabled by the host-guest interaction between 
cyclodextrin and adamantane for targeted saRNA delivery was investigated. We show that 
while increasing the degree of mannosylation stifles in vitro transfection efficiency, it enhances 
the percentage of cells expressing the saRNA in human skin explants. Furthermore, it was 
investigated that increasing the ratio of polymer to saRNA also enhanced the protein expression 
ex vivo, which was specifically due to an increase in epithelial cell expression. Meanwhile, 
increasing the degree of mannosylation also increased expression specifically in epithelial 
cells. We believe that this platform, which enables glycosylation of PEI through host-guest 
chemistry, is a highly clinically translational delivery vehicle and is dually useful for targeting 
specific cell types for saRNA delivery and expression. 
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